The FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide ...

Newron Pharmaceuticals further expands its intellectual property portfolio for Evenamide with a new EU composition of matter ...

This summer, Viva Premium is revisiting the best and biggest stories of 2025. The below story was first published in February ...

Did you know that problems with getting an erection when aroused can be your body's way of telling you to take a look at your ...

Investing.com -- Altimmune (NASDAQ:ALT) stock surged 14% Monday after the company announced that its liver disease treatment pemvidutide received Breakthrough Therapy Designation from the U.S. Food ...

Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with ...

Understanding what autoimmune diseases are, what triggers them and how they’re treated can be a powerful first step toward ...

Possible Reasons, and The Best Labs for Fatigue Key Takeaways: Fatigue describes more than just feeling sleepy — it’s a ...

At age 51, I was diagnosed with severe rheumatic mitral stenosis. After a second round of tests, treatment was changed from open-heart surgery to balloon valvuloplasty. What can ...

Cardiovascular disease remains a leading global cause of death, and we break down its pathology, risk factors, and the ...

The sinus of your heart has nothing to do with your nose as you might guess; it’s a structure in the right atrium where blood ...